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Hepatitis E virus (HEV) is a member of the genus Orthohepevirus in the family Hepeviridae and the causative agent of hepa-
titis E in humans. HEV is a major health problem in developing countries, causing mortality rates up to 25% in pregnant
women. However, these cases are mainly reported for HEV genotype (gt)1, while gt3 infections are usually associated with
subclinical courses of disease. The pathogenic mechanisms of adverse maternal and fetal outcome during pregnancy in
HEV-infected pregnant women remain elusive. In this study, we observed that HEV is capable of completing the full viral
life cycle in placental-derived cells (JEG-3). Following transfection of JEG-3 cells, HEV replication of both HEV gts could
be observed. Furthermore, determination of extracellular and intracellular viral capsid levels, infectivity, and biophysical prop-
erties revealed production of HEV infectious particles with similar characteristics as in liver-derived cells. Viral entry was
analyzed by infection of target cells and detection of either viral RNA or staining for viral capsid protein by immunoﬂuores-
cence. HEV gt1 and gt3 were efﬁciently inhibited by ribavirin in placental as well as in human hepatoma cells. In contrast,
interferon-a sensitivity was lower in the placental cells compared to liver cells for gt1 but not gt3 HEV. Simultaneous deter-
mination of interferon-stimulated gene expression levels demonstrated an efﬁcient HEV-dependent restriction in JEG-3.
Conclusion: We showed differential tissue-speciﬁc host responses to HEV genotypes, adding to our understanding of the
mechanisms contributing to fatal outcomes of HEV infections during pregnancy. Using this cell-culture system, new thera-
peutic options for HEV during pregnancy can be identiﬁed and evaluated. (Hepatology Communications 2018;2:173-187)
Introduction
Hepatitis E virus (HEV) is a major cause ofviral hepatitis and is classiﬁed in the genusOrthohepevirus and the family Hepeviridae.(1)
Its genome contains a positive-oriented single-
stranded RNA with three open reading frames (ORF),
of which ORF1 encodes a multifunctional polyprotein
involved in RNA replication, ORF2 the viral capsid
protein, and ORF3 a nonstructural protein that can
function as a viroporin.(2,3) HEV infections in humans
are caused by ﬁve genotypes (gts) that differ in their
worldwide distribution, their hosts, and their route of
transmission. Viruses of gt1 and gt2 are found mainly
in developing countries and are transmitted by the
fecal–oral route. They solely infect humans and show
high epidemic potential, causing up to 120,000 symp-
tomatic cases in a single outbreak.(4) Viruses of gt3 and
gt4 cause zoonotic infections transmitted mainly by
contaminated food or transfusion of contaminated
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blood products.(5) It has been shown that gt7 can be
transmitted from infected dromedaries by undercooked
ﬂesh and milk.(6) HEV infections can cause arthralgia,
vomiting, weakness, loss of appetite, abdominal pain,
and hepatitis with accompanied symptoms, including
jaundice and itching.(7) However, clinical symptoms
occur in only 2%-5% of patients with acute HEV infec-
tion, as indicated by vaccine trials where more than
110,000 Chinese individuals were followed.(8) In appar-
ent cases, mortality rates are estimated to be between
0.5% and 3%,(9) leading to up to 70,000 deaths world-
wide per year.(10) Ribavirin (RBV) remains the treat-
ment of choice in chronic infections and can be
considered in fulminant cases.(11-13) However, RBV
administration should be carefully considered because of
possible side effects,(11) in particular anemia and treat-
ment failure due to the selection of viral mutants with
increased replication ﬁtness.(14-16) Of note, RBV is also
contraindicated in pregnant individuals. To date, only
one prophylactic vaccine has been licensed (Hecolin),(8)
which is currently not available outside of China.
One striking feature of HEV is the development of
extrahepatic manifestations, including neurologic inju-
ries, pancreatitis, acute thrombocytopenia, aplastic ane-
mia, and renal disease.(17) Maternal mortality rates of
about 25% in association with fulminant hepatic failure
have been observed in HEV-infected pregnant
women,(18) and the human placenta was also implicated
as an extrahepatic replication site of HEV. Notably,
vertical transmission has been shown to occur fre-
quently,(19) and adverse fetal outcome, especially in the
third trimester, include preterm delivery, abortion, still-
birth, and intrauterine fetal and neonatal death.(18,20,21)
However, the underlying pathologic and virologic
mechanisms of an HEV gt1 infection during pregnancy
remain largely undeﬁned.
In this study, we investigated whether HEV is capa-
ble of completing the whole viral life cycle in human
placental-derived cells and if there are genotype-speciﬁc
replication differences. Viral replication was assessed
after transfection with HEV subgenomic replicons and
a full-length genomic clone. Viral assembly and release
were studied by the detection of intracellular and extra-
cellular viral capsid levels as well as by associated infec-
tivity and subsequent viral entry by infection with gt1
and gt3 virions. In addition, we evaluated HEV suscep-
tibility to antiviral compounds and interferon (IFN) in
placental-derived cells. Collectively, the results implicate
productive HEV replication in the placenta with a
potent restriction of host immune responses.
Materials and Methods
COMPOUNDS
IFN-a2a was obtained from the human IFN sam-
pler (PBL Biomedical Laboratories, Piscataway, NJ).
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RBV was received from either Sigma-Aldrich (St. Louis,
MO) or ICN Pharmaceuticals (Costa Mesa, CA).
Sofosbuvir was received from selleckchem.com (Munich,
Germany). All compounds were stored and diluted
according to the manufacturer’s recommendations.
GAUSSIA LUCIFERASE
MEASUREMENT
We measured Gaussia luciferase activity in superna-
tants of transfected cells at 4, 24, 48, and 72 hours
posttransfection (p.t.) (replication kinetic assay) or 72
hours p.t. (compound dose-response assay). Brieﬂy,
20 lL of supernatant per well was transferred to a
white, ﬂat-bottom, 96-well microplate followed by
the detection of luminescence using a microplate
reader (Centro XS3 LB960; Berthold Technologies,
Bad Wildbad, Germany) with coelenterazine as a
substrate.
HEV CONSTRUCTS AND IN VITRO
TRANSCRIPTION
A plasmid construct containing the full-length
HEV genome (Kernow-C1 p6 clone, gt3; GenBank
accession number JQ679013) and two constructs har-
boring a subgenomic HEV sequence coupled with a
Gaussia luciferase reporter gene, of which one contains
the gt1 Sar55/S17 strain (based on clone pSK-E2;
GenBank accession no. AF444002, with insertion of
an S17 sequence in the hypervariable region) and one
the Kernow-C1 p6, were used to generate HEV
in vitro transcripts as described.(22-24) Capping was
performed using Ribom7G Cap Analog (Promega,
Madison, WI).
CELL CULTURE
The human liver cell line HepG2 and Huh7-
derived S10-3 human hepatoma cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (Invitrogen,
Karlsruhe, Germany). The HepG2/C3A subclone cells
were cultured in Eagle’s minimum essential medium
(MEM) with glutamine (Invitrogen). The choriocarci-
noma cell lines JEG-3 (ATCC Number HTB-36,
established by serial cloning of BeWo; DNA proﬁle
similar to BeWo; produce human chorionic gonado-
tropin, human chorionic somatomammotrophin, and
progesterone; ethnicity, unknown; sex, male), BeWo
(ATCC Number CCL-98, established from a malig-
nant gestational choriocarcinoma of the fetal placenta;
gonadotropin, lactogen, and steroid secreting; ethnic-
ity, unknown; sex, male), and JAR (ATCC Number
HTB-144, directly established from a trophoblastic
tumor of the placenta; genes for estrogen, progester-
one, human chorionic gonadotropin, and human cho-
rionic somatomammotropin expressed; ethnicity,
Caucasian; sex, male) were cultured in Advanced
MEM (Invitrogen). Supplements included 15% fetal
calf serum (FCS) for BeWo cells, 10% ultra-low
immunoglobulin G FCS for HepG2/C3A cells, and
10% FCS for all other cell lines, along with 2mM
L-glutamine, 1% nonessential amino acids (Invitro-
gen), 100mg/mL gentamicin (Invitrogen) for the
HepG2/C3A cells, and 100 lg/mL of streptomycin
and 100 IU/mL of penicillin (Invitrogen) for all other
cell lines. Additionally, 1% sodium pyruvate was added
for HepG2/C3A and JEG-3 cells. HepG2 and
HepG2/C3A cells were further grown on rat collagen-
coated (SERVA Electrophoresis GmbH, Heidelberg,
Germany) culture plates. Cells were kept at 37 8C in a
5% (volume/volume) CO2 incubator.
HEV REPLICATION ASSAY
For transfection, we used the electroporation tech-
nique in accordance with previous reports.(25) In brief,
4-93 106 cells/mL in 400lL of Cytomix containing
2mM adenosine triphosphate and 5mM glutathione
were mixed with 3 lg of the respective in vitro tran-
scribed HEV RNA. After electroporation with a Gene
Pulser system (Bio-Rad, Munich, Germany), cells
were immediately transferred into 10-15mL of the
respective culture medium. Cell suspensions were
seeded into 12-well plates (1mL per well, electropora-
tion with subgenomic HEV RNA), 24-well plates,
partly provided with glass coverslips (500 lL per well,
electroporation with full-length HEV RNA) or 96-
well plates (50 lL per well, electroporation with subge-
nomic HEV RNA). Four hours p.t., medium was
replaced (only in 12-well and 24-well plates) and fresh
culture ﬂuid or medium containing compounds at
indicated concentrations was added. At indicated time
points p.t., the supernatant was collected and cells
were lysed, ﬁxed, or subjected to a freeze–thaw cycle
prior to further analysis.
DETECTION OF HEV ANTIGEN
At 4, 24, 48, and 72 hours p.t., the cell culture
supernatant and cells were harvested. The cells were
scraped in 1mL of fresh culture ﬂuid and lysed by
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three freeze and thaw cycles. Subsequently, the antigen
content in cell lysates and supernatants was determined
by a commercially available enzyme-linked immuno-
sorbent assay (ELISA) (Wantai Biopharmaceuticals
Inc., Beijing, China) as described.(26) In this assay,
antigen (ORF2-encoded capsid protein) is captured
using goat polyclonal anti-HEV antibodies, and anti-
gen detection is visualized with enzyme-linked mono-
clonal antibodies against the ORF2-encoded capsid
protein. We added 100lL of (diluted) sample to each
reaction, and the assay was performed in accordance
with the manufacturer’s instructions.
GENOTYPE 1 AND 3 HEV
INFECTION AND DETECTION
Cell culture-derived infectious HEV (HEVcc)
based on the gt3 Kernow-C1 strain was generated as
described,(27) and primary isolate gt1 strain Sar55
(1.213 108 viral RNA copies/mL) in 10% fecal sus-
pension from infected macaques was obtained from
Suzanne U. Emerson (National Institutes of Health).
Approximately 53 105 genome equivalents of gt1
Sar55 or gt3 p6 were used to infect 23 104 JEG-3
cells or S10-3 cells for 12-16 hours, followed by
removal of the inoculum by thorough washes with cul-
ture medium. Seven days postinfection, cells were ﬁxed
in 4% paraformaldehyde in phosphate-buffered saline
(PBS) at room temperature for 10 minutes and
blocked with 10% goat serum, 1% bovine serum albu-
min, and 0.1% Triton X-100 in PBS (PBTG buffer)
at room temperature for 2 hours. Cells were incubated
with anti-ORF2 in PBTG (1:200) for 2 hours at room
temperature, followed by several washes with PBS.
Secondary antibody conjugated to Alexa Fluor 594
(Thermo Fisher Scientiﬁc) in PBTG buffer (1:1,000)
was added and incubated at room temperature for 1
hour, followed by several washes with PBS. For the
determination of production of infectious particles in
JEG-3 and HepG2 cells, cells were transfected as
described and treated in accordance to a reported pro-
tocol.(28) Brieﬂy, cells were electroporated as described
above, incubated 6-7 days in Eagle’s MEM with ultra-
low immunoglobulin G FCS, and cell growth was
stopped by adding hydroxyurea where necessary.
Supernatant was concentrated in Amicon Ultra cen-
trifugal ﬁlter units, molecular weight cutoff 10 kDa
(Merck Millipore, Tullagreen, Ireland) to harvest
extracellular virus, and cells were lysed in fresh medium
by freeze and thaw cycles to harvest intracellular virus.
Extracellular and intracellular virus of the same
concentration were used for infection of HepG2/C3A
cells to quantify virus infectivity. These virus stocks
were also used for density gradient centrifugation.
INDIRECT
IMMUNOFLUORESCENCE
At 48 hours p.t. or 7 days postinfection, transfected
cells previously seeded onto coverslips or on 96-well-
plates were ﬁxed with 3% PFA in PBS and permeabi-
lized with 0.5% Triton X-100 in PBS. After blocking
of nonspeciﬁc binding with 5% goat serum (Sigma-
Aldrich) and horse serum (Gibco) in PBS, immunos-
taining of ORF2-encoded capsid protein was per-
formed. A 1:1,000 PBS-diluted mouse antibody
directed against the ORF2-encoded protein (amino
acids 434-457, clone 1E6; LifeSpan BioSciences, Inc.,
Seattle, WA) or a 1:500 dilution of an ORF2-speciﬁc
rabbit hyperimmune serum (kindly provided by R.
Ulrich, Friedrich Loefﬂer Institute, Greifswald, Ger-
many) was added. A ﬂuorescently labelled goat anti-
body (AlexaFluor 488; Life Technologies) was used at
a dilution of 1:1,000 in PBS with 5% goat or horse
serum to detect bound primary antibodies. DNA was
labelled with 40,60-diamidino-2-phenylindole (Life
Technologies). For quantiﬁcation of virus infectivity,
wells were manually observed for speciﬁc ﬂuorescence,
and the presence of ﬂuorescent foci was recorded. A
ﬂuorescent focus was deﬁned as a minimum of two
adjacent cells showing clear intracytoplasmic ﬂuores-
cence. The number of ﬂuorescent foci was counted in
the highest dilution showing ﬂuorescence, and the
respective focus-forming units (FFU) were calculated.
The limit of detection was 1 FFU.
STATISTICS
GraphPad Prism 7.03 software was used for data
analysis using either two-way analysis of variance of
log-transformed values followed by Tukey’s multiple
comparisons test or an unpaired t test with Welch’s
correction, or repeated measures one-way analysis
of variance of log-transformed values followed by
Dunnett’s multiple comparison test, as indicated
in the ﬁgure legends. P< 0.05 was considered
signiﬁcant.
For additional information on Materials and
Methods, please refer to the Supporting Information
for this article.
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Results
HEV GENOTYPE 1 AND 3 STRAINS
ARE REPLICATING IN
PLACENTAL-DERIVED
CELL LINES
Three different placental-derived choriocarcinoma
cell lines, JEG-3, BeWo, and JAR, were examined for
replication of HEV subgenomic reporter viruses of gt1
(strain Sar55, clone Sar55/S17) and gt3 (Kernow-C1
p6). The reporter viruses harbor a Gaussia luciferase,
which replaces parts of the ORF2 gene.(23) The human
hepatocellular carcinoma cell line HepG2 was tested as
a positive control in parallel, and RBV was used as an
HEV RNA replication inhibitor. JEG-3 and BeWo
placental-derived cells supported replication over time
of HEV gt1 and of gt3 even more efﬁciently (Fig. 1).
In both genotypes, replication was blocked by RBV.
In contrast, JAR cells displayed no productive gt1 rep-
lication and very low gt3 reporter activity (Fig. 1). The
liver-derived HepG2 cells showed efﬁcient replication
of both HEV gts (Fig. 1). In summary, gt1 and gt3
HEV replicons were able to replicate in two different
placental-derived cell lines.
PLACENTAL-DERIVED JEG-3
CELLS SUPPORT FULL-LENGTH
HEV REPLICATION AND
PRODUCTION OF
INFECTIOUS PARTICLES
Based on these results, JEG-3 cells were used in
subsequent experiments for HEV replication kinetics
as these cells were similar to those observed in HepG2
cells (Fig. 1). In addition, JEG-3 cells are widely
accepted as a placental and trophoblastic in vitro model
system.(29,30) We next assessed whether JEG-3 cells
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FIG. 1. Replication of subgenomic HEV genotype 1 and 3 in different placental-derived cell lines. Different cell lines JEG-3,
BeWo, JAR, and HepG2 were transfected by electroporation with HEV RNA of gt1 strain Sar55/S17 and gt3 strain Kernow-C1 p6
reporter constructs and were left untreated (black circles) or treated with 100mM RBV (gray triangles) 4 hours p.t. Gaussia luciferase
activity was assessed at 4, 24, 48, and 72 hours p.t. and normalized to 4-hour values. Depicted are the mean values of three indepen-
dent experiments6 SEM. Abbreviation: RLU, relative light unit.
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support replication of full-length HEV RNA by
transfection of gt3 HEV p6 (not harboring a reporter
gene) following detection by quantitative reverse-
transcription polymerase chain reaction (qRT-PCR)
targeting the ORF1 gene. Accumulation of HEV
RNA could be detected in JEG-3 cells at similar
levels observed in HepG2 cells. In both cell lines,
HEV RNA copy numbers were decreased by RBV
treatment (Fig. 2A). To visualize HEV antigen expres-
sion in JEG-3 cells, immunoﬂuorescence staining with
ORF2-speciﬁc antibodies was performed. Capsid-
positive cells were detectable, which was not the case
for the RBV-treated cells (Fig. 2B).
Next, we examined whether placental-derived
JEG-3 cells were capable of assembling and releasing
HEV particles by quantiﬁcation of ORF2-encoded
capsid protein by speciﬁc ELISA performed on both
the lysate of transfected cells (intracellular) as well as
the respective supernatant (secreted) (Fig. 3A). Extra-
cellular capsid protein increased over time in both
compartments, indicating efﬁcient virus assembly and
release in both cell types (Fig. 3A). RBV treatment of
transfected cells reduced both intracellular and extra-
cellular capsid levels (Fig. 3A). The production of
HEV infectious particles from JEG-3 cells in com-
parison to liver cells was determined as follows: The
intracellular infectivity of JEG-3 cells was approxi-
mately 23 103 FFU/mL, which is one order of
magnitude lower compared to the extracellular-
associated infectivity (Fig. 3B, left panel). In HepG2
cells, the intracellular infectivity was higher with
13 105 FFU/mL and the extracellular infectivity
about 100-fold lower (Fig. 3B, right panel). To assess
the difference in particle composition between pla-
centa- and liver-derived cell lines, we performed a
gradient analysis of intracellular and extracellular
HEVcc, including an NP-40 detergent treatment to
disrupt potential viral particle-associated membranes.
For both cell types, extracellular viral RNA levels
peaked at a density of approximately 1.10-1.15 g/mL
(Fig. 3C). Treatment with NP-40 shifted the peak of
viral RNA to a higher density, implicating a potent
disruption of potential membrane structures. Intracel-
lularly, HEV RNA levels were present at higher den-
sities, suggesting mainly nonenveloped viral particles
with minor effects of the NP-40 treatment. However,
in JEG-3-derived cells, about 20% of the viral RNA
was also detected at densities comparable to the extra-
cellular particles. HEV antigen levels were also
detected by the Wantai capsid ELISA for all fractions
and demonstrated antigen levels at density fractions
that were not associated with HEV RNA (Fig. 3C).
Collectively, JEG-3 placental-derived cells supported
full-length RNA replication, viral assembly, and
release and the production of infectious particles with
similar biophysical properties.
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FIG. 2. Replication of full-length HEV
and detection of intracellular and extracel-
lular capsid protein. JEG-3 and HepG2
cells were transfected by electroporation
with full-length HEV RNA gt3 Kernow-
C1 p6 and were left untreated (black bars)
or treated with 100 mM RBV (gray bars)
4 hours p.t. (A) Viral replication in each
cell line was measured by qRT-PCR 4,
24, 48, and 72 hours p.t. in cell lysates.
(B) Immunoﬂuorescence detection of
HEV antigen in paraformaldehyde-ﬁxed
JEG-3 cells 48 hours p.t. with ORF2-
encoded antigen (green) and with DAPI
(blue). Abbreviation: DAPI, 4’,6-diami-
dino-2-phenylindole.
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JEG-3 CELLS ARE PERMISSIVE
FOR INFECTION WITH HEVcc
To evaluate if JEG-3 cells allowed HEV entry and
replication, cells were infected with HEVcc and viral
RNA released over time was detected in the cell cul-
ture supernatants as described for human liver
cells(12,25) in comparison to RBV-treated cells. An
increase in viral RNA postinfection was observed, and
this reached 6.27 log10 RNA copies/mL in the culture
medium, indicating the productive infection of JEG-3
(Fig. 4A). Treatment with 50 mM RBV was able to
efﬁciently inhibit HEV replication after infection
(decrease of 4.5 log10 RNA copies). Because infection
with cell culture-grown HEV gt1 particles is not yet
possible, we next performed infection of JEG-3 cells
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with a gt1 Sar55 primary isolate stool suspension not
harboring the S17 insertion derived from infected rhe-
sus macaques.(31) Further controls included HEVcc
gt3 particles and infection of Huh-7 human
hepatoma-derived cell line S10-3, which is highly per-
missive for HEVcc replication.(31) Challenged cell
lines were stained for ORF2-encoded antigen 7 days
postinfection. The gt1 primary isolate infection
resulted in only a few ORF2-positive S10-3 cells; these
cells were not seen with the JEG-3 cells (Fig. 4B).
Anti-ORF2-positive cells could readily be detected in
JEG-3 and S10-3 cells after gt3 HEVcc infection, con-
ﬁrming the previous results (Fig. 4B). Together, gt1-
derived primary HEV infection efﬁciency was limited
in human liver cells and not detectable in placental-
derived cells. However, JEG-3 cells supported viral
entry and productive replication of gt3 HEVcc detected
by qRT-PCR and immunoﬂuorescence.
ANTIVIRAL PROPERTIES OF
SOFOSBUVIR AND IFN-a2a IN
JEG-3 CELLS
Although no approved drugs for HEV infections are
available, IFN-a2a and RBV have been used as off-
label medications in chronically infected patients.
Recently, sofosbuvir (SOF), a direct-acting antiviral
inhibiting the NS5B protein of hepatitis C virus,(32)
has been shown to exert antiviral activity against
HEV.(27) Therefore, we evaluated the effect of these
drugs in extrahepatic placental cells replicating HEV
gt1 and gt3. SOF treatment alone showed no signiﬁ-
cant inhibition of gt1 replication in placental-derived
(Fig. 5A) and liver-derived cells (Fig. 5B). Gt3 repli-
cons were signiﬁcantly inhibited 72 hours p.t. by SOF
in JEG-3cells but only moderately affected in HepG2
cells, and RBV as well as the combination of both
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FIG. 5. Antiviral activity of sofosbuvir in placental-derived JEG-3 cells. (A) JEG-3 and (B) HepG2 cells were transfected by electro-
poration with HEV RNA of gt1 strain Sar55/S17 and gt3 strain Kernow-C1 p6 reporter constructs. Cells were treated with either
100 mM RBV (gray inverted triangles), 10mM SOF (gray triangles), or with a combination of 10mM SOF and 100mM RBV (dark
gray boxes) 4 hours p.t. Gaussia luciferase activity was determined at 4, 24, 48, and 72 hours p.t. and normalized to 4-hour values.
Bar plots of data points representing the luciferase activity 72 hours p.t. for each cell line and gt illustrate the maximum replication
inhibition. Depicted are the mean values of at least three independent experiments6 SEM (*P< 0.05; **P< 0.01; ***P< 0.001;
****P< 0.0001; repeated measures one-way analysis of variance of log-transformed values followed by Dunnett’s multiple comparison
test). Abbreviations: ns, not signiﬁcant; RLU, relative light unit.
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demonstrated high antiviral activities in both cell lines
(Fig. 5A,B). We next determined the susceptibility of
HEV gts to IFN-a2a in JEG-3 cells. There was a
moderate dose-dependent inhibition of gt3 replication
up to 50%; however, no effect of IFN on gt1-
dependent replication of the Sar55/S17 replicon was
observed (Fig. 6A). A comparison of reporter activity
of both gts at the highest IFN dose of 250 ng/mL
illustrates the higher susceptibility of the gt3 replicon
to IFN-a2a (Fig. 6A, right panel). In contrast, in
HepG2 cells a dose-dependent reduction in HEV rep-
lication efﬁciency was noted for both strains (Fig. 6B),
indicating a lower IFN sensitivity of the gt1 strain in
the placental-derived cells. To exclude defects in the
cellular innate immune response of the placental-
derived cells or impairment in activating the SOF pro-
drug, we compared expression proﬁles of genes
involved in IFN signaling and sensing between JEG-3
cells and primary human trophoblasts by differential
expression analysis of a published RNA sequencing
data set(30) (Supporting Fig. S1). SOF is metabolized
to its active triphosphate form through hydrolysis of
the carboxylate ester by either cathepsin A or carboxy-
lesterase 1, followed by cleavage of the phosphorami-
date by histidine triad nucleotide-binding protein 1,
and subsequently repeatedly phosphorylated by nucleo-
side diphosphate kinase 1 and 2 (NME1/2).(33) Three
transcripts of genes involved in IFN signaling (IFN
gamma receptor 1 [IFNGR1], interleukin 10 receptor
subunit beta [IL10RB], and signal transducer and acti-
vator of transcription 1 [STAT1]) and two transcripts
of genes involved in SOF activation (NME1, NME1-
NME2) are signiﬁcantly differentially expressed (Sup-
porting Fig. S1A). Their raw expression values in reads
per kilobase of exon model per million mapped reads,
however, are in ranges considered as tissue speciﬁcally
expressed (Supporting Fig. S1B). Furthermore, the
majority of genes involved in type I IFN signaling and
sensing (IFN alpha and beta receptor subunit
[IFNAR1, IFNAR2], IFNGR2, IFN lambda receptor
1 [IFNLR1], IFN regulatory factor 9 [IRF9], Janus
kinase [JAK1, JAK2], STAT2, and tyrosine kinase 2)
showed a similar expression level in both primary
human trophoblasts as well as JEG-3 cells, suggesting
a comparable cellular response to exogenous IFN-a2a
treatment. Next, we performed western blot analysis of
the phosphorylation of STAT1 at its Y701 phosphory-
lation site in both cell lines replicating HEV gt3 and
gt1 as well as transfer RNA (tRNA) as control. Our
objective was to investigate whether the lower sensitiv-
ity of the gt1 strain in JEG-3 cells is due to a perma-
nent phosphorylation of STAT1 in this cell line.
HepG2 cells transfected with the gt3 replicon show
phosphorylation of STAT1 without exogenous IFN
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treatment, whereas after transfection with the gt1
replicon or control tRNA, phosphorylation occurs
only after exogenous IFN treatment (Fig. 6C).
This effect might be due to endogenous activation
of upstream RNA-sensing mechanisms because
replication efﬁciency is highest in HepG2 cells
transfected with the gt3 replicon. In JEG-3 cells,
phosphorylation of STAT1 can be observed only
after exogenous IFN administration for all three
conditions (Fig. 6C), suggesting activation of JAK-
STAT signaling following treatment with IFN in
these cells. In summary, differences in the IFN
sensitivity speciﬁcally for HEV gt1 were noted
between JEG-3 and HepG2 cells, and these might
play a role in the pathogenic mechanisms observed
in HEV infections during pregnancy.
INTERFERON-STIMULATED
GENE EXPRESSION IS
DOWN-REGULATED BY
HEV IN PLACENTAL-DERIVED
JEG-3 CELLS
As different studies have reported that HEV is able
to counteract the IFN-stimulated gene (ISG) response
in human liver cells,(34,35) we next investigated the viral
restriction of the IFN pathway by determination of
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ISG expression after HEV transfection in placental-
derived cells. JEG-3 (Fig. 7A) and HepG2 (Fig. 7B)
cells were transfected with gt1 and gt3-based subge-
nomic HEV constructs or a tRNA transfection con-
trol. We treated 24-hour p.t. cells with IFN-a2a. Four
or 24 hours posttreatment, cells were lysed and mes-
senger RNA levels of the ISGs IFN-induced protein
with tetratricopeptide repeats (IFIT1, IFIT3) and MX
dynamin-like guanosine triphosphatase 1 (Mx1) were
assessed with qRT-PCR and normalized to untreated
cells. Both HEV strains blocked IFN type I responses
by a signiﬁcant down-regulation of the three measured
ISGs 4 hours and 24 hours posttreatment in JEG-3
cells (Fig. 7A). Notably, the gt1 strain, which repli-
cated less efﬁciently in JEG-3 cells compared to the
gt3 strain (Fig. 1), displayed a similar potency in viral
restriction of IFIT1 and Mx1 4 hours posttreatment.
In HepG2 cells, a comparable down-regulation could
be observed, particularly for IFIT3 4 hours posttreat-
ment and Mx1, which were induced about 50-fold to
100-fold in the control cells 4 hours posttreatment
(Fig. 7B). In conclusion, HEV gts were able to exert a
potent anti-IFN response in the placental-derived
cells.
Discussion
The course of HEV infection during pregnancy has
a more severe outcome compared to other populations
and can lead to fulminant hepatitis, increasing mater-
nal and fetal mortality.(36) However, the pathogenic
mechanisms responsible for these fatal outcomes
remain elusive. In this study, we characterized human
placental-derived cells for their permissiveness to HEV
replication and analyzed antiviral mechanisms by drug
treatment as well as host innate immune responses. By
the detection of HEV negative-strand RNA and anti-
gen using immunohistochemistry in placental tissue
sections of infected pregnant woman, extrahepatic rep-
lication in the placenta has been postulated.(37) We
report here that the placental-derived cell line JEG-3
supported replication of gt1 and gt3 with efﬁciency
similar to human liver cells (Figs. 1 and 2). The reason
for the lower replication rate of gt1 and gt3 in
placenta-derived JAR cells compared to JEG-3 and
BeWo cells is currently unclear; however, this could be
due to a differential host factor expression required for
efﬁcient HEV replication. The ﬁrst HEV outbreak
with reported cases of symptomatic pregnant women
was documented in 1987 in Nepal,(38) and most of the
recent gt1 outbreaks were detected in refugee camps in
developing countries, including Somalia,(39) Kenya,(40)
Sudan,(41) and Uganda.(9) There are, in addition,
reports mainly from Egypt in which gt1 infections dur-
ing pregnancy were not associated with morbidity.(42-
44) Importantly, a few cases of gt3 infection during
pregnancy were also observed in industrialized coun-
tries, for example, in a study from the United King-
dom,(45) France,(46) and Germany.(47) Nevertheless,
these cases do not indicate a comparable severe out-
come of gt3 infections during pregnancy. Of note,
high viral loads of HEV during pregnancy have been
implicated as one of the factors responsible for the
severity of the infection during pregnancy.(48,49) JEG-
3 cells allowed HEV viral particle production with
membrane-associated extracellular viral particles and
biophysical properties comparable to human liver cell-
derived viruses (Fig. 3). HEV antigen was determined
by a commercially available ELISA and revealed capsid
protein also in fractions where no viral RNA was
detected. These results are in line with a recent study
by Montpellier et al.(50) that identiﬁed three different
forms of the viral capsid whereby two of these ORF2
forms are not associated with infectious particles. In
addition, we could previously show that HEV antigen
in sera from HEV-infected patients was detectable
throughout all fractions of the gradients, suggesting
the presence of distinct fragments of the viral capsid
proteins with different densities.(26) Importantly, JEG-
3 cells allowed entry and spread of HEV gt3 strain p6
(Fig. 4). The infection with primary material of the
Sar55 genotype 1 isolate was restricted to human liver
cells, but the infection efﬁciency was limited. Recently,
Nair et al.(51) described a novel protein, termed ORF4,
which is gt1 speciﬁc and implicated in the endoplasmic
stress response promoting viral replication. If ORF4 is
expressed during pregnancy in HEV infection in vivo
and how this protein interacts with the host response
require future investigation. Using the JEG-3 replica-
tion system described herein may facilitate future
advances in understanding this important phenome-
non. Similar to our reference hepatoma cell line
HepG2, RBV efﬁciently inhibited HEV replication in
placental-derived JEG-3 cells. As placental cells are
also likely a site of extrahepatic viral replication and
RBV is contraindicated in case of pregnancy, this cell
model could be used as a tool for the identiﬁcation and
evaluation of new antivirals for HEV infection in this
cohort. SOF has previously been shown to lower HEV
replication and in combination with RBV demon-
strated an additive effect.(27) Here, we observed
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moderate effects of SOF in both cell lines, and gt1 rep-
lication seemed less sensitive to inhibition by SOF,
probably due to the low replication efﬁciency of the
gt1-based Sar55/S17 replicon.
Alteration of the immune system during hormonal
changes in pregnancy has been discussed as another
potential pathogenic mechanism in HEV infec-
tion,(36,42) but the described alterations mostly affect
cellular immunity. According to McConkey and col-
leagues,(30) two-dimensional-cultured JEG-3 cells
secrete only small amounts of beta-human chorionic
gonadotropin, and production of human placental lac-
togen was also reduced, limiting studies of endogenous
hormone-driven inﬂuences of HEV infection on the
IFN response. However, the already moderate inhibi-
tion of HEV replication by IFN-a in human liver cell
lines(34) was even weaker in the placental-derived cell
line selective for gt1 replication (Fig. 6), while both
HEV gts were able to efﬁciently down-regulate
selected ISGs in the liver- and placental-derived cell
line (Fig. 7). These differences in placenta-speciﬁc
innate immune responses might be a relevant factor for
the clinical features of HEV during pregnancy, and
future studies are required to dissect the underlying
mechanism of this phenomenon. One possible hypoth-
esis could be differential interaction with host factors
inﬂuencing IFN responsiveness. As HEV genotyping
is not always routinely performed, in vivo evidence to
support this hypothesis has not been acquired. Animal
model systems to recapitulate HEV infection during
pregnancy are further limited. Inoculation of pregnant
rhesus monkeys with HEV gt1 could not detect differ-
ences when comparing with nonpregnant monkeys
and failed to reproduce the elevated mortality rates
seen in pregnant women or the development of the
reported severe and fulminant hepatitis E.(52) Recently,
experimental infection of pregnant rabbits with HEV
demonstrated high mortality and vertical transmission.
However, pathogenic mechanisms have not been
addressed and are difﬁcult to compare with the course
of infection in HEV-infected pregnant women.(53)
In conclusion, we found that HEV was capable of
performing the full viral life cycle in a placental-
derived cell line expanding HEV tissue tropism. Fur-
ther, these data revealed differential tissue-speciﬁc host
responses to HEV genotypes, implicating a mechanis-
tic role in the severe outcome of HEV infection during
pregnancy.
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